Summary of Study ST002546
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001639. The data can be accessed directly via it's Project DOI: 10.21228/M8V41D This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002546 |
| Study Title | Lipidomic profile of Toxplasma gondii-infected mice (Negative mode MS) |
| Study Summary | Cachexia is a life-threatening disease characterized by chronic, inflammatory muscle wasting and systemic metabolic impairment. Despite its high prevalence, there are no efficacious therapies for cachexia. Mice chronically infected with the protozoan parasite Toxoplasma gondii represent a novel animal model recapitulating the chronic kinetics of cachexia. To understand how perturbations to metabolic tissue homeostasis influence circulating metabolite availability we used mass spectrometry analysis. Despite the significant reduction in circulating triacylglycerides, nonesterified fatty acids, and glycerol, sphingolipid long-chain bases and a subset of phosphatidylcholines (PCs) were significantly increased in the sera of mice with T. gondii infection-induced cachexia. In addition, the TCA cycle intermediates -ketoglutarate, 2- hydroxyglutarate, succinate, fumarate, and malate were highly depleted in cachectic mouse sera. Sphingolipids and their de novo synthesis precursors PCs are the major components of the mitochondrial membrane and regulate mitochondrial function consistent with a causal relationship in the energy imbalance driving T. gondii-induced chronic cachexia. |
| Institute | University of Virginia |
| Last Name | Feng |
| First Name | Tzu-Yu |
| Address | 345 Crispell Dr. |
| ttf4ye@virginia.edu | |
| Phone | 702-217-4454 |
| Submit Date | 2023-04-06 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-04-20 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001639 |
| Project DOI: | doi: 10.21228/M8V41D |
| Project Title: | Metabolomic study on the chronic Toxoplasma gondii infection in mice. |
| Project Type: | Untargeted MS |
| Project Summary: | Cachexia is a life-threatening disease characterized by chronic, inflammatory muscle wasting and systemic metabolic impairment. Despite its high prevalence, there are no efficacious therapies for cachexia. Mice chronically infected with the protozoan parasite Toxoplasma gondii represent a novel animal model recapitulating the chronic kinetics of cachexia. To understand how perturbations to metabolic tissue homeostasis influence circulating metabolite availability we used mass spectrometry analysis. Despite the significant reduction in circulating triacylglycerides, nonesterified fatty acids, and glycerol, sphingolipid long-chain bases and a subset of phosphatidylcholines (PCs) were significantly increased in the sera of mice with T. gondii infection-induced cachexia. In addition, the TCA cycle intermediates alpha-ketoglutarate, 2- hydroxyglutarate, succinate, fumarate, and malate were highly depleted in cachectic mouse sera. Sphingolipids and their de novo synthesis precursors PCs are the major components of the mitochondrial membrane and regulate mitochondrial function consistent with a causal relationship in the energy imbalance driving T. gondii-induced chronic cachexia. |
| Institute: | University of Virginia |
| Last Name: | Feng |
| First Name: | Tzu-Yu |
| Address: | 345 Crispell Dr. |
| Email: | ttf4ye@virginia.edu |
| Phone: | 702-217-4454 |
Subject:
| Subject ID: | SU002646 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Factor |
|---|---|---|
| SA255658 | Toxoplasma infected-4 | Infected |
| SA255659 | Toxoplasma infected-7 | Infected |
| SA255660 | Toxoplasma infected-3 | Infected |
| SA255661 | Toxoplasma infected-2 | Infected |
| SA255662 | Toxoplasma infected-6 | Infected |
| SA255663 | Toxoplasma infected-5 | Infected |
| SA255664 | Toxoplasma infected-1 | Infected |
| SA255665 | Toxoplasma infected-8 | Infected |
| SA255666 | Uninfected-6 | Uninfected |
| SA255667 | Uninfected-4 | Uninfected |
| SA255668 | Uninfected-8 | Uninfected |
| SA255669 | Uninfected-3 | Uninfected |
| SA255670 | Uninfected-2 | Uninfected |
| SA255671 | Uninfected-5 | Uninfected |
| SA255672 | Uninfected-7 | Uninfected |
| SA255673 | Uninfected-1 | Uninfected |
| Showing results 1 to 16 of 16 |
Collection:
| Collection ID: | CO002639 |
| Collection Summary: | Serum collected from T. gondii-infected mice at 9 wk post-infection. Serum samples from uninfected mice were included as controls. |
| Sample Type: | Blood (serum) |
Treatment:
| Treatment ID: | TR002658 |
| Treatment Summary: | 10–14-week-old male C57BL/6 mice were infected with 10 Me49 bradyzoite cysts by intraperitoneal infection resuspended in 200 Μl PBS per mouse using a 5G 5/8” tuberculin syringe. |
Sample Preparation:
| Sampleprep ID: | SP002652 |
| Sampleprep Summary: | Serum samples were stored at -80C before the mass spectrometry assay. |
Combined analysis:
| Analysis ID | AN004193 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Waters Acquity |
| Column | Waters ACQUITY UPLC CSH C18 (100 x 2.1mm,1.7um) |
| MS Type | ESI |
| MS instrument type | QTOF |
| MS instrument name | Agilent 6530 QTOF |
| Ion Mode | NEGATIVE |
| Units | peak heights |
Chromatography:
| Chromatography ID: | CH003107 |
| Instrument Name: | Waters Acquity |
| Column Name: | Waters ACQUITY UPLC CSH C18 (100 x 2.1mm,1.7um) |
| Column Temperature: | 65 |
| Flow Gradient: | 15%-99% |
| Flow Rate: | 0.6 ml/min |
| Solvent A: | 60% water/40% acetonitrile; 5 mM ammonium formate; 0.1% formic acid |
| Solvent B: | 90% isopropanol/10% methanol; 5 mM ammonium formate; 0.1% formic acid |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS003940 |
| Analysis ID: | AN004193 |
| Instrument Name: | Agilent 6530 QTOF |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | Samples extracted using Matyash extraction procedure which includes MTBE, MeOH, and H2O. The organic (upper) phase was dried down and submitted for resuspension and injection onto the LC while the aqueous (bottom) phase was dried down and submitted to derivatization for GC. They are resuspended with 110 uL of a solution of 9:1 methanol: toluene and 50 ng/mL CUDA. This is then shaken for 20 seconds, sonicated for 5 minutes at room temperature, and then centrifuged for 2 minutes at 16100 rcf. The samples are then aliquoted into three parts. 33 uL are aliquoted into a vial with a 50 uL glass insert for positive and negative mode lipidomics. The last part is aliquoted into an eppendorf tube to be used as a pool. The samples are then loaded up on an Agilent 1290 Infinity LC stack. The positive and negative mode were run on an Agilent 6530 with a scan range of m/z 120-1200 Da with an acquisition speed of 2 spectra/s. Between 0.5 and 2 uL were injected onto a Waters ACQUITY UPLC CSH C18 1.7um 2.1x100mm Column with VanGuard PreColumn 2.1x5 mm . The gradient used is 0 min 15% (B), 0–2 min 30% (B), 2–2.5 min 48% (B), 2.5–11 min 82% (B), 11–11.5 min 99% (B), 11.5–12 min 99% (B), 12–12.1 min 15% (B), 12.1–15 min 15% (B) with a flow rate of 0.6 mL/min. The mass resolution for the Agilent 6530 is 10,000 for ESI (+). |
| Ion Mode: | NEGATIVE |
